Disclosure Of Interests In Other Entities [Text Block]

Xbrane Biopharma - Filing #689990

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31
Disclosure of interests in other entities [text block]	—	—		—	—	—	—	—	—	—	—	—	—
Disclosure of interests in subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [text block]	—	—		—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [abstract]
Disclosure of subsidiaries [line items]
Profit (loss), attributable to non-controlling interests	—	—	– SEK	—	—	—	—	—	—	—	– SEK	—	—
Non-controlling interests	– SEK	—	—	—	—	—	– SEK	—	—	—	—	—	—
Current assets	513 524 SEK	—	—	—	—	—	561 008 SEK	—	—	—	—	—	—
Non-current assets	176 990 SEK	—	—	—	—	—	127 418 SEK	—	—	—	—	—	—
Current liabilities	236 569 SEK	—	—	—	—	—	219 667 SEK	—	—	—	—	—	—
Non-current liabilities	29 058 SEK	—	—	—	—	—	37 019 SEK	—	—	—	—	—	—
Revenue	—	—	57 618 SEK	—	—	—	—	—	—	—	10 709 SEK	—	—
Profit (loss)	—	—	172 513 SEK	—	172 513 SEK	—	—	—	—	—	188 376 SEK	188 376 SEK	—
Comprehensive income	—	– SEK	167 356 SEK	– SEK	172 513 SEK	5 157 SEK	—	– SEK	– SEK	1 220 SEK	187 156 SEK	188 376 SEK	—
Disclosure of interests in associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [abstract]
Disclosure of associates [line items]
Profit (loss) from continuing operations	—	—	168 513 SEK	—	—	—	—	—	—	—	183 226 SEK	—	—
Profit (loss) from discontinued operations	—	—	4 001 SEK	—	—	—	—	—	—	—	5 150 SEK	—	—
Other comprehensive income	—	—	5 157 SEK	—	—	5 157 SEK	—	—	—	1 220 SEK	1 220 SEK	—	—
Disclosure of interests in joint arrangements [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [text block]	—	—		—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [abstract]
Disclosure of joint ventures [line items]
Cash and cash equivalents	193 994 SEK	—	—	—	—	—	295 180 SEK	—	—	—	—	—	243 139 SEK
Tax expense (income)	—	—	– SEK	—	—	—	—	—	—	—	– SEK	—	—